Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Do polynucleotides stimulate collagen? Reading the evidence behind the claim

Laboratory studies can show collagen-related activity, but this is not the same as proving that an injectable polynucleotide will create a visible or lasting improvement for every patient.

5 minute read

‘Collagen stimulation’ can mean several different things

Collagen provides structural support within skin, and the phrase ‘stimulates collagen’ is often used to explain regenerative treatments. However, a study may measure collagen-related genes in cultured cells, collagen protein in a tissue sample, dermal density on imaging or a visible change in wrinkles. These outcomes are related, but they are not interchangeable.

An increase in a laboratory marker does not tell us how much new, well-organised collagen forms in living human facial skin, whether somebody will notice a difference or how long it will last. The exact molecule, concentration, formulation, delivery method, treatment area and number of sessions also affect whether one result can be applied to another product.

What do laboratory and wound studies show?

A 2026 study examined a PDRN-containing product in an animal full-thickness wound model. Treated wounds showed more collagen deposition and microvessels than untreated controls during the first 14 days. This supports a biological effect during wound repair, but healing an experimental open wound is not the same as improving intact, ageing human skin after a cosmetic injection.

Another 2026 investigation tested a topical medium-length PDRN in human fibroblasts, reconstructed skin and ultraviolet-damaged skin outside the body. It reported activation of collagen-related pathways and increased extracellular-matrix proteins. The associated human study used an eye cream—not an injectable—and lasted 28 days, so it cannot prove the effect of a different injected polynucleotide formulation.

Clinical measurements do not always confirm the mechanism

In a randomised split-face trial of 27 people, one side received a polynucleotide injectable and the other a non-cross-linked hyaluronic-acid product. Both sides improved, and the polynucleotide side showed greater changes in some elasticity, hydration, roughness and pore measurements. However, improvement in dermal density was not significantly different between the two sides.

That does not mean no collagen-related effect occurred; dermal density is an indirect measurement and the study was small. It does show why a proposed mechanism should not be presented as a guaranteed clinical result. Photographs, patient satisfaction and device measurements can each answer different questions, and none alone proves newly formed collagen.

The overall evidence remains limited

A 2026 systematic review found only seven randomised PN and PDRN trials with 183 participants across skin rejuvenation, postoperative scar prevention and wound healing. Products, schedules, treatment areas and outcomes varied, while individual studies included between 10 and 42 analysed participants and followed people for two weeks to six months.

The review found promising signals but concluded that larger, standardised trials with longer follow-up are needed. Results from PDRN should not automatically be applied to PN, and topical, injected and wound-care formulations should not be grouped together. Current evidence supports describing a plausible regenerative action with uncertainty—not promising that a set amount of collagen will be produced.

Downtime and adverse effects still matter

Even when the aim is gradual skin remodelling, the procedure involves multiple injections. Stinging, tenderness, redness, swelling, itching, small raised points, pinpoint bleeding and bruising can occur. Improvement may be subtle or absent, and several sessions increase the total treatment burden as well as cost and exposure to injection-related risk.

Increasing pain, spreading redness or heat, discharge, fever, marked swelling, persistent lumps, unusual pale or mottled skin, eye pain or visual symptoms need prompt clinical assessment. Small trials cannot reliably identify uncommon complications. Sterile technique, authentic traceable product, written aftercare and access to clinical review are essential.

Suitability and expectations must be individual

Consultation should define the concern—such as dryness, fine lines, texture or scarring—and check whether the evidence matches it. Medical conditions, medicines, allergies including fish allergy where relevant, previous reactions, pregnancy or breastfeeding, active infection or inflammation and planned procedures must be reviewed. Product ingredients and instructions matter.

Alternatives may include skincare, sun protection, another procedure or no treatment. A useful discussion focuses on the likely visible change rather than a biological slogan, and covers uncertainty, number of sessions, downtime, cost and follow-up. GMC guidance requires honest information about risks and lower-risk options before a cosmetic intervention is agreed.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment